-transparent.png){kind=logo}
Fifty evaluable patients with advanced lung cancer (28 small cell and 22 non-small cell carcinomas), mainly pretreated by chemotherapy, received 4'-epi-doxorubicin 90 mg/m2 every 3 weeks. Two partial responses were obtained in small cell lung cancer patients, which lasted 153 and 168 days. Leukopenia, emesis and alopecia were the most frequent side effects. Two patients who previously received anthracyclines died suddenly of cardiac failure, another patient had severe congestive heart failure, and four others had minor cardiac dysfunctions. 4'-epi-doxorubicin has a modest activity in advanced lung cancer, mainly pretreated by chemotherapy and is not devoid of significant cardiotoxicity in this patient population.
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
June 1988,
Tumori,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
January 1984,
Cancer chemotherapy and pharmacology,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
October 1984,
Cancer treatment reports,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
April 1984,
Cancer treatment reports,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
June 1983,
Cancer treatment reports,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
January 1984,
Journal of cancer research and clinical oncology,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
December 1984,
Cancer treatment reports,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
January 1985,
Cancer treatment reports,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
January 1984,
Investigational new drugs,
G Giaccone, and
M Donadio, and
G Bonardi, and
V Iberti, and
A Calciati
January 1985,
Cancer treatment reports,
